______________________________ 10/22/2008 Tomophase To Exhibit First In-Vivo Cross-Sectional Images Of Pulmonary Stenting Using Proprietary Oct System

______________________________ 10/16/2007 Tomophase To Exhibit First Cross-Sectional Images Of Human Bronchus Using Proprietary OCT System

______________________________

11/23/2005 Tomophase Corporation Closes $4.5 M Series A Financing Round

______________________________

news and events

Tomophase To Exhibit First In-Vivo Cross-Sectional Images Of Pulmonary Stenting Using Proprietary Oct System

Results Displayed at CHEST Meeting in October 2008

BURLINGTON, MA – October 22, 2008 – Tomophase Corporation announced today that it will display the first in-vivo cross-sectional images of implanted pulmonary stents using their proprietary optical coherence tomography (“OCT”) system at the CHEST meeting in Philadelphia, October 27th through October 29th. The images were captured using the Tomophase OCT System as part of an ongoing research collaboration with Dr. Armin Ernst, Director of Interventional Pulmonology and Dr. Hisashi Tsukada, Research Associate, at Beth Israel Deaconess Medical Center in Boston, Massachusetts.  

The Tomophase OCT System enables the interventional pulmonologist to clearly visualize sub-epithelial tissue structures in the airway. The system, which is not yet FDA-approved, utilizes a near-infrared emitting probe in a catheter which is integrated with a conventional video bronchoscope. The images captured by the research team at Beth Israel are from in vivo animal model tracheal tissue. During the next several months the Company plans to continue this work as it progresses towards use of the system in human clinical studies.  

”Our goal at Tomophase is to use our proprietary optical technology to help clinicians image subsurface pulmonary tissue at a level of resolution currently unavailable, while not exposing the patient to potentially harmful radiation, UV light or contrast agents” commented Dr. Peter Norris, CEO of Tomophase. “Much of the structure in the airways beneath the epithelial layer is essentially invisible to clinicians. Providing real-time access to this information could provide major benefits to both diagnostic and therapeutic approaches to many pulmonary diseases. We believe this research collaboration with Beth Israel Deaconess is an important first step in establishing the utility of this breakthrough technology in both research and the clinic”.  

“These latest imaging results from the Tomophase OCT system show excellent detail in the region surrounding the implanted stent,” commented Dr. Ernst. “As such, it may ultimately prove very useful to clinicians in understanding the detailed nature of the interaction between the stent material, including those made from bio-absorbable materials, and the surrounding tissue. High resolution, cross-sectional OCT imaging technology may also have the potential to provide real-time evaluation of other drug and device/tissue interactions as well.”        

### END ###

.

Tomophase To Exhibit First Cross-Sectional Images
Of Human Bronchus Using Proprietary OCT System

Results Displayed at CHEST Meeting in October 2007

BURLINGTON, MA – October 16, 2007 – Tomophase Corporation announced today that it will display the first cross-sectional images of excised human bronchial tissue using their proprietary optical coherence tomography (“OCT”) system at the CHEST meeting in Chicago, October 22nd through October 24th.  The images were captured using the Tomophase OCT System as part of an ongoing research collaboration with Dr. Armin Ernst, Director of Interventional Pulmonology, at Beth Israel Deaconess Medical Center in Boston, Massachusetts. 

The Tomophase OCT System enables the interventional pulmonologist to clearly visualize sub-epithelial tissue structures in the airway.  The system, which is not yet FDA-approved, utilizes a near-infrared emitting probe in a catheter which is integrated with a conventional video bronchoscope. The images captured by the research team at Beth Israel are from ex vivo human bronchial tissue.  During the next several months the Company plans to further this work in real-time in vivo clinical studies.    

”Our goal at Tomophase is to use our proprietary optical technology to help clinicians image subsurface tissue at a level of resolution currently unavailable, while not exposing the patient to potentially harmful radiation, UV light or contrast agents” commented Dr. Norris, CEO of Tomophase.  “We believe this research collaboration with Beth Israel Deaconess is an important first step in the introduction of this breakthrough technology into both the research and clinical settings.

“The initial imaging results from the Tomophase OCT system show remarkable clarity at greater tissue depths than other existing optical imaging technologies” commented Dr. Ernst.  “As such, it may ultimately prove useful to clinicians in the enhanced evaluation of various pulmonary disease states.  High resolution OCT technology may also have the potential to provide real-time image evaluation of drug/tissue interactions.  This ability may provide new insight regarding the treatment of pulmonary conditions such as asthma and COPD.”

About Tomophase Corporation

Tomophase Corporation is a private company founded in 2003 based on proprietary technology innovations in the field of optical coherence tomography and its use to image tissue at high resolution.  With Tomophase OCT, researchers and clinicians can observe tissue structure within 2-3 mm of the surface without the use of radiation, UV light or image contrast agents.  Tomophase is pursuing the first application of its technology in pulmonary medicine for the visualization of airways.  Future development areas include respiratory therapy development, lung cancer management and surgical guidance.

More information on Tomophase Corporation can be found on the World Wide Web at www.tomophase.com.

### END ###

.

 

TOMOPHASE Corporation Closes $4.5 M Series A Financing Round

Burlington, MA - November 23, 2005 - Tomophase Corporation, a leading developer of non-invasive opto-medical devices, announces the completion of a $4.5 M Series A round of private equity financing. The capital raised will fund continuing product development and manufacturing as well as clinical development activities.
The financing round was led by Sanderling Biomedical Venture Capital in conjunction with a private investor group from the original seed round of financing.

“The funding decision by Sanderling is a strong endorsement of our patented approach to opto-medical devices and our business direction. Sanderling has many years of experience in bringing medical devices to the marketplace and we look forward to collaborating with them on the commercialization of our multi-modal tissue analyzer,” said Dr. Feiling Wang, President.

Dr. Peter Norris, CEO, commented, “Tomophase now has the means to proceed with an active staffing program aimed at attracting the best optic and electronics talent available to join us in our committed attack on some of the most deadly diseases. Based on initial discussions with several leading first wave adopters at top clinical centers, we expect rapid deployment and acceptance as the standard of care as clinical trials are completed.”

Tomophase devices address the needs in oncological and cardiovascular medicine where early and minimally invasive diagnosis is key to successful treatments. The company’s initial focus will be applying its technology to the early stage diagnosis and treatment of lung cancer, the worlds leading cause of cancer death. If detected in an early stage, the 5 year survival rate of the lung cancer patients is over 85%. However, the early stage is asymptomatic and detection is primarily by chance. After the patients present with symptoms, the 5 year survival rate drops to 10-15%. Screening via CT scan may soon be accepted for high risk groups to reveal the presence of solitary pulmonary nodules (SPNs). Currently there is no means to differentiate between malignant and benign SPNs other than pulmonary biopsy, itself a risky procedure. Tomophase has patented technology which will, in conjunction with existing tools, enable the early-stage diagnosis in a non-invasive and reliable way.

Tomophase Corporation is a privately held, developmental stage opto-medical devices company has headquarters in Burlington, MA. Tomophase was founded in 2003 and is focused on the development and commercialization of its patented technology for minimally invasive opto-medical devices.

### END ###

◙ back to top